Voxelotor Patent Expiration
Voxelotor is Used for increasing hemoglobin levels and treating sickle cell disease by administering Voxelotor orally to patients. It was first introduced by Global Blood Therapeutics Inc
Voxelotor Patents
Given below is the list of patents protecting Voxelotor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oxbryta | US10493035 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Oct 12, 2037 | Global Blood Theraps |
| Oxbryta | US11020382 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Dec 02, 2036 | Global Blood Theraps |
| Oxbryta | US11944612 | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Dec 02, 2036 | Global Blood Theraps |
| Oxbryta | US10722502 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Feb 06, 2035 | Global Blood Theraps |
| Oxbryta | US11452720 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Feb 06, 2035 | Global Blood Theraps |
| Oxbryta | US9447071 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | Feb 06, 2035 | Global Blood Theraps |
| Oxbryta | US9248199 | 1:1 adducts of sickle hemoglobin | Jan 29, 2034 | Global Blood Theraps |
| Oxbryta | US9018210 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | Nov 25, 2033 | Global Blood Theraps |
| Oxbryta | US10017491 | Compounds and uses thereof for the modulation of hemoglobin | Dec 28, 2032 | Global Blood Theraps |
| Oxbryta | US10034879 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | Dec 28, 2032 | Global Blood Theraps |
| Oxbryta | US10806733 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | Dec 28, 2032 | Global Blood Theraps |
Voxelotor's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Voxelotor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Assessing Physical Function in Sickle Cell Patients Taking Voxelotor | Inova Health Care Services | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease | Pfizer | NA |
TERMINATED
(Mar 1, 2026)
| PHASE3 |